MedTrace Logo

Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)

NCT05739929 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-03-22

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the colchicine protective effect in patients undergoing Percutaneous Coronary Intervention (PCI). The main question it aims to answer is: does initiating colchicine before planned PCI will reduce post-procedural myocardial injury? Half of the participants will receive colchicine, while the other half will receive a placebo.

Conditions

Interventions

DRUG

Colchicine 0.5 MG Oral Tablet

0.5 mg colchicine tablets twice daily.

DRUG

Placebo

Placebo tablets twice daily

Sponsors & Collaborators

  • Helwan University

    lead OTHER

Principal Investigators

  • Mohammed A Ammar, MD, MSc · Helwan University, Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739929 on ClinicalTrials.gov